AML Hub: Recent Episodes
Scientific Education Support
The AML Hub is an open-access online resource dedicated to providing balanced, credible, and up-to-date medical education on acute myeloid leukemia (AML). Our aim is to enhance knowledge in AML through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.
See acast.com/privacy for privacy and opt-out information.
During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, Michal Bar-Natan, Weill Cornell Medicine, New York, US, shared her highlights with the AML Hub.
Hosted on Acast. See acast.com/privacy for more information.
During the 6th European CAR T-Cell Meeting, the AML Hub spoke to Sarah Tettamanti, Tettamanti Foundation Research Center, Monza, IT. We asked, What are the challenges associated with CAR T-cell therapy in patients with AML?
Hosted on Acast. See acast.com/privacy for more information.
The AML Hub spoke to Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK at ASH 2023. We asked, How might the MORPHO trial of gilteritinib impact clinical practice?
Hosted on Acast. See acast.com/privacy for more information.
The AML Hub was pleased to speak to Gail Roboz, Weill Cornell Medicine, New York, US, and Naval Daver, MD Anderson Cancer Center, Houston, US. We asked about risk stratification and guidelines in acute myeloid leukemia (AML) management.
Firstly, Roboz and Daver discuss the impact of blast count on the diagnosis of AML and how a patient's mutational profile can affect treatment decisions. They highlight available, effective lower-intensity and targeted therapies and a potential transition to a fully genomic- and cytogenetic-based classification of AML. Finally, they discuss current patient selection strategies for intensive induction chemotherapy and future directions in AML treatment.
Hosted on Acast. See acast.com/privacy for more information.
During the virtual 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke with Eleni Gavriilaki, George Papanikolaou General Hospital of Thessaloniki, Thessaloniki, GR. We asked, How are new fludarabine conditioning combinations impacting transplant outcomes?
Gavriilaki begins by discussing a study presented at EBMT 2022 that explored outcomes of fludarabine + treosulfan, which followed on from previous studies exploring treosulfan. Gavriilaki details the study design and patient population, explaining which comparative therapies were used and why. Finally, Gavriilaki outlines different studies presented at EBMT covering fludarabine combinations for patients with AML and MDS.
During the EHA2021 Virtual Congress, the AML Hub spoke with Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, Should pre-transplant measurable residual disease (MRD) be used to guide treatment in AML?
Nagler begins by discussing the importance of MRD in AML treatment and transplantation. He highlights the significance of MRD in different settings as a prognosis factor and describes the result of his study presented at EHA2021. Finally, he outlines the current treatment landscape for transplants in relation to MRD status and makes recommendations for MRD-positive patients.
During the EHA2021 Virtual Congress, the AML Hub spoke with Charles Craddock, Queen Elizabeth Hospital Birmingham, Birmingham, UK. We asked, Should pre-transplant minimal residual disease (MRD) be used to guide treatment in acute myeloid leukemia (AML)?
Craddock begins by outlining the reasons for the increased use of allogeneic transplant and reviews data that discuss the exclusion criteria and benefits of transplant. He goes on to discuss how patient outcomes could be improved and the importance of post-transplant maintenance. Finally, he highlights the need to generate prospective data, referring to the ongoing studies COSI and AMADEUS.
During the EHA2021 Virtual Congress, the AML Hub spoke with Gert Ossenkoppele, Amsterdam UMC, Amsterdam, NL. We asked, Should pre-transplant minimal residual disease (MRD) be used to guide treatment in acute myeloid leukemia (AML)?
Ossenkoppele begins by outlining emerging techniques in MRD, such as next-generation sequencing. He goes on to describe how risk category and MRD status can inform treatment decisions, such as for allogeneic stem cell transplant.
During the 2021 TCT Meetings Digital Experience, the AML Hub spoke to Farhad Ravandi, MD Anderson Cancer Center, Houston, US. We asked, Can HMA maintenance therapy improve eligibility for HSCT?
Ravandi begins by highlighting the limited maintenance approaches for patients with AML. He continues with the promising results from the QUAZAR AML-001 study evaluating oral azacitidine (CC-486), an oral hypomethylating agent, which can be used for maintenance and to improve eligibility for hematopoietic stem cell transplantation.
See acast.com/privacy for privacy and opt-out information.
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Andrew Wei, The Alfred Hospital, Melbourne, AU, and Natasha S. Anstee, The Alfred Hospital & Monash University,Melbourne, AU. We asked, Does sorafenib plus intensive chemotherapy improve outcome in FLT3-internal tandem duplication (FLT3-ITD) AML?
Wei starts by introducing the clinical study data from AMLM16, a randomized, placebo-controlled trial evaluating sorafenib versus placebo in combination with intensive chemotherapy for previously untreated adult patients with FLT3-ITD AML. In this study, sorafenib did not improve event-free survival when combined with intensive chemotherapy; Wei discusses the possible causes of this result and the subgroups that did better in the sorafenib arm. Anstee then reports the results from the correlative studies evaluating the impact of sorafenib on phospho-FLT3 inhibition and the presence of FLT3-ITD measurable residual disease after chemotherapy.
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Daniel Pollyea, University of Colorado School of Medicine, Aurora, US, about venetoclax combinations in patients with AML with IDH1/2 mutations.
Clinical studies evaluating the combination of venetoclax + azacitidine versus azacitidine alone have shown that patients with AML with IDH1/2 mutations treated with venetoclax + azacitidine achieved higher response rates, and had better outcomes, compared with patients treated with azacitidine alone.
In this podcast, Pollyea discusses the results of a study further evaluating the efficacy and safety of venetoclax + azacitidine in treatment-naïve patients with AML with IDH1/2 mutations unfit for intensive treatment. Data were combined from two different studies: a phase Ib study where patients were treated with venetoclax + azacitidine and the VIALE-A study (NCT02993523) comparing patients treated with venetoclax + azacitidine versus placebo + azacitidine.
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Naval Daver, MD Anderson Cancer Center, Houston, US, about venetoclax combinations in patients with FLT3-mutated AML.
Emerging data on venetoclax combinations in patients with FLT3-mutated AML have been presented at ASH 2020. FLT3 mutations are the most common mutations in patients with AML.
In this podcast, Daver discusses the results of a study comparing the combination of azacitidine plus venetoclax versus azacitidine plus placebo in patients with FLT3-mutated AML. He also talks about a study evaluating the combination of gilteritinib with venetoclax in patients with relapsed/refractory FLT3-mutatedAML and reports the results of the first combination of decitabine + venetoclax + FLT3 inhibitor of clinician’s choice in patients with FLT3-mutatedAML.
During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Courtney D. DiNardo, MD Anderson Cancer Center, Houston, US, about the use of venetoclax combinations in mutation subtypes of AML.
In this podcast, DiNardo gives an overview of the studies on venetoclax combinations presented at ASH 2020, especially venetoclax plus azacitidine, in mutation subtypes of AML.
DiNardo focuses on three specific subgroups: patients with IDH1/2 mutations; patients with FLT3 mutations; and patients with TP53 mutations. After talking about the promising results reported at ASH, DiNardo pointed out that unmet needs still exist, especially for patients with TP53 mutations.
During the European School of Haematology (ESH) 2nd How to Diagnose and Treat: Acute Leukaemia meeting, the AML Hub spoke to Jorge Sierra, Hospital de la Santa Creu i Sant Pau, Barcelona, ES. In this podcast, Jorge Sierra talks about how close we are to offering treatment tailored to mutational profile.
Jorge Sierra describes the clinical benefit of adding drugs that target mutations into treatment regimens and explains the importance of mutational profiling at diagnosis and relapse to determine treatment options. He discusses target therapies that are available to patients, including the following:
- midostaurin (FLT3 inhibitor) for the frontline setting
- ivosidenib (IDH1 inhibitor) for the relapsed/refractory (R/R) setting
- enasidenib (IDH2 inhibitor) for the R/R setting
- gilteritinib (FLT3 inhibitor) for the R/R setting
He concludes by discussing other novel agents that have shown efficacy in the treatment of AML, including venetoclax and gemtuzumab ozogamicin.
See acast.com/privacy for privacy and opt-out information.
During the 25th Congress of the European Hematology Association (EHA), the AML Hub spoke to a member of our steering committee, Naval Daver, The University of Texas MD Anderson Cancer Center, Houston, US, about novel approaches and emerging therapies for TP53 AML.
Identification of disease-driving genetic aberrations has allowed for major advancements in the AML setting. TP53 mutations are observed in around 15% of patients with AML, with distinct patterns between patient subsets. Despite the development of targeted therapies, such as FLT3 and IDH1/2 inhibitors, treatments targeting TP53 mutations are yet to be established.
TP53-mutant AML is an area of unmet need, demonstrating high interpatient heterogeneity. Here, Naval Daver describes the efforts being made to establish TP53 as a therapeutic target, with the aim to further improve patient outcomes.
During the American Association of Cancer Research (AACR) Virtual Annual Meeting I, the AML Hub was pleased to speak to Christine Spencer, Parker Institute for Cancer Immunotherapy, San-Francisco, US and Diwakar Davar, University of Pennsylvania Medical Center, Pittsburgh, US. We asked: how can we use the microbiome to improve cancer immunotherapy and alleviate side effects such as graft-versus-host-disease?
In this podcast, Dr Davar starts by providing a background on the importance of the microbiome in adaptive and innate immunity, while Dr Spencer states the importance of the cross-talk between the microbiome and immune system through microbial products, peptides, and metabolites. Dr Davar then explains the concept of immunosurveillance, immunoediting, and checkpoint inhibitors. Dr Spencer describes fecal microbiome transplant studies that showed features of the microbiome can predict response to immunotherapy and effect T-cell expression. Dr Davar then describes some of the studies that are looking at fecal microbiome transplant in combination with checkpoint inhibitors. He goes on to discuss studies investigating the use of live bacterial products to elicit the same effects as fecal microbiome transplant, particularly the mediation of CD8 T cells. Dr Spencer also talks about probiotics, antibiotics, and diet and explains how this can affect the gut microbiome and describes studies looking at these features in terms of response to immunotherapies. She also describes the microbiome research related to graft-versus-host-disease and the impact of higher alpha diversity on post-transplant survival, while Dr Davar explains how the microbiome may also affect toxicity and side-effects of cancer immunotherapies.
See acast.com/privacy for privacy and opt-out information.
During the 25th Congress of the European Hematology Association (EHA), the AML Hub hosted a discussion between David Sallman, Moffitt Cancer Center, Tampa, US, and Steering Committee Member Naval Daver, MD Anderson Cancer Center, Houston, US.
The question was, Is CD47-directed antibody therapy safe and effective in patients with AML and myelodysplastic syndromes?
CD47 is a dominant negative immune checkpoint expressed by cancer cells, which facilitates immune evasion by decreasing recognition by macrophages. Increased expression of CD47 on cancer cells has been associated with inferior survival in patients with AML. The first-in-class anti-CD47 antibody magrolimab reinstates macrophage-mediated phagocytosis of tumor cells and has demonstrated anti-tumor activity in preclinical models.
Here, David Sallman and Naval Daver discuss the potential and clinical status of CD47-directed antibody therapy for the treatment of AML and myelodysplastic syndromes.
During the American Society of Clinical Oncology (ASCO) Annual Meeting, Alexander Maurer from the AML Hub hosted a group discussion with Michael Ozga and Caner Saygin, both from The Ohio State University, Columbus, US and Abhay Singh from Roswell Park Comprehensive Cancer Center, Buffalo, US. This podcast discusses how the type of prior treatment can affect the risk of therapy-related myeloid neoplasms.
The group start by discussing the problems clinicians face when deciding treatment plans for patients with secondary myeloid neoplasms and describe how exposure to prior DNA damaging agents, cytotoxic therapies, and genotoxic therapies, can lead to a complex karyotype in these patients.
The group then discuss the role of clonal hematopoiesis in the evolution of secondary myeloid neoplasms. Dr Saygin describes how this could be a possibility especially for TP53 mutated, therapy-related AML, he also provides another hypothesis that genotoxic agents could cause de novo mutations. The group also discuss other driving mutations for clonal hematopoiesis including MPN1, SRSF2, and ASXL1, before moving on to discuss how specific genotoxic therapies can generate specific mutations. Dr Saygin and Dr Ozga describe their study in which they analyzed the molecular footprint of patients who had received various genotoxic and cytotoxic agents in order to answer this. Dr Singh also discusses his data on how the development of novel agents, such as immunotherapies may actually reduce the risk of secondary myeloid neoplasms compared to previous treatment options.
The discussion ends on the note that these types of studies will eventuality allow clinicians to predict disease risk better and provide more suitable therapies based on the patient's particular molecular profile.
See acast.com/privacy for privacy and opt-out information.